Nigel S. Key

Nigel S. Key

Auto-generated profile, based on publicly available information

Nigel S. Key

Department of Medicine Division of Hematology and Blood Research Center University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NKNigel S. Key
Nigel S. Key
AKAlok A. Khorana
Alok A. Khorana
NKNicole M. Kuderer
Nicole M. Kuderer
KBKari Bohlke
Kari Bohlke
ALAgnes Y.Y. Lee
Agnes Y.Y. Lee
Anna FalangaAnna Falanga
Anna Falanga
PURPOSE: To conduct an update of the ASCO venous thromboembolism (VTE) guideline. METHODS: After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was performed for two guideline questions: perioperative thromboprophylaxis and treatment of VTE. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) published between November 1, 2018, and June 6, 2022. RESULTS: Five RCTs provided information that contributed to changes to the 2019 recommendations. Two RCTs addressed direct factor Xa inhibitors (either rivaroxaban or apixaban) for extended thromboprophylaxis after surgery. Each of these postoperative trials had important limitations but suggested that these two oral anticoagulants are safe and effective in the settings studied. An additional three RCTs addressed apixaban in the setting of VTE treatment. Apixaban was effective in reducing the risk of recurrent VTE, with a low risk of major bleeding. RECOMMENDATIONS: Apixaban and rivaroxaban were added as options for extended pharmacologic thromboprophylaxis after cancer surgery, with a weak strength of recommendation. Apixaban was also added as an option for the treatment of VTE, with high quality of evidence and a strong recommendation. Additional information is available at www.asco.org/supportive-care-guidelines .

23 February 2017 in Blood
Verified
Journal Article
Open access
PDF file
DNDenis F. Noubouossie
Denis F. Noubouossie
MWMatthew F. Whelihan
Matthew F. Whelihan
YYYuan-Bin Yu
Yuan-Bin Yu
ESErica Sparkenbaugh
Erica Sparkenbaugh
RPRafal Pawlinski
Rafal Pawlinski
NKNigel S. Key
Nigel S. Key
Key Points: Individual histone proteins and DNA purified from normal human neutrophils promote coagulation activation. Neither intact NETs nor nucleosomes directly promote coagulation activation in plasma in vitro.

1 August 2007 in The Lancet
Verified
Journal Article
Closed access
NKNigel S Key
Nigel S Key
CNClaude Negrier
Claude Negrier

16 May 2019 in Blood
Verified
Journal Article
Open access
PDF file
DNDenis F. Noubouossie
Denis F. Noubouossie
BRBRANDI REEVES
BRANDI REEVES
Brian D. StrahlBrian D. Strahl
Brian D. Strahl
NKNigel S. Key
Nigel S. Key
Reactive and clonal neutrophil expansion has been associated with thrombosis, suggesting that neutrophils play a role in this process. However, although there is no doubt that activated monocytes trigger coagulation in a tissue factor-dependent manner, it remains uncertain whether stimulated neutrophils can also directly activate coagulation. After more than a decade of debate, it is now largely accepted that normal human neutrophils do not synthetize tissue factor, the initiator of the extrinsic pathway of coagulation. However, neutrophils may passively acquire tissue factor from monocytes. Recently, the contact system, which initiates coagulation via the intrinsic pathway, has been implicated in the pathogenesis of thrombosis. After the recent description of neutrophil extracellular trap (NET) release by activated neutrophils, some animal models of thrombosis have demonstrated that coagulation may be enhanced by direct NET-dependent activation of the contact system. However, there is currently no consensus on how to assess or quantify NETosis in vivo, and other experimental animal models have failed to demonstrate a role for neutrophils in thrombogenesis. Nevertheless, it is likely that NETs can serve to localize other circulating coagulation components and can also promote vessel occlusion independent of fibrin formation. This article provides a critical appraisal of the possible roles of neutrophils in thrombosis and highlights some existing knowledge gaps regarding the procoagulant activities of neutrophil-derived extracellular chromatin and its molecular components. A better understanding of these mechanisms could guide future approaches to prevent and/or treat thrombosis.

10 January 2007 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
SPSílvia Perez‐Pujol
Sílvia Perez‐Pujol
PMPaul H. Marker
Paul H. Marker
NKNigel S. Key
Nigel S. Key
Background: Platelet‐derived microparticles (MPs) are believed to play an important role in coagulation and inflammatory disorders. Unfortunately, MP size renders them difficult to study and analyze by conventional flow cytometry.Methods: We analyzed and characterized platelet‐derived MPs, using antibodies against the major surface glycoproteins (GP), the platelet activation antigen P‐selectin (CD62P), and a marker of procoagulant activity (phosphatidylserine exposure). MPs were generated by exposure of platelets to thrombin receptor activating peptide (TRAP) or ionophore. Both agonists induced significant microvesiculation of platelets, and the resulting MPs were analyzed by a new digital flow cytometer: Becton‐Dickinson FACSAria™.Results: Membrane GPs were equally well represented in MPs generated by either reagent. In contrast, P‐selectin was more intensely expressed in TRAP‐MPs, while phosphatidylserine (PS) expression was markedly increased in ionophore‐MPs. Two distinct populations of TRAP‐MPs (one PS‐positive and another PS‐negative) were apparent. The latter characteristic facilitated sorting of MPs according to their PS exposure.Conclusions: The data presented herein show a significant improvement in the methodology applied until now to the characterization of MPs. The ability to characterize and sort MP subpopulations may help to resolve their contributions to normal and pathological functions. © 2007 International Society for Analytical Cytology

22 July 2019 in British Journal of Cancer
Verified
Journal Article
Open access
ECElena Campello
Elena Campello
AIAnton Ilich
Anton Ilich
PSPaolo Simioni
Paolo Simioni
NKNigel S. Key
Nigel S. Key
It has long been recognised that pancreatic cancer induces a hypercoagulable state that may lead to clinically apparent thrombosis. Although the relationship between pancreatic cancer and hypercoagulability is well described, the underlying pathological mechanism(s) and the interplay between these pathways remain a matter of intensive study. This review summarises existing data on epidemiology and pathogenesis of thrombotic complications in pancreatic cancer with a particular emphasis on novel pathophysiological pathways. Pancreatic cancer is characterised by high tumoural expression of tissue factor, activation of leukocytes with the release of neutrophil extracellular traps, the dissemination of tumour-derived microvesicles that promote hypercoagulability and increased platelet activation. Furthermore, other coagulation pathways probably contribute to these processes, such as those that involve heparanase, podoplanin and hypofibrinolysis. In the era in which heparin and its derivatives-the currently recommended therapy for cancer-associated thrombosis-might be superseded by direct oral anticoagulants, novel data from mouse models of cancer-associated thrombosis suggest the possibility of future personalised therapeutic approaches. In this dynamic era for cancer-associated thrombosis, the discovery of novel prothrombotic and proinflammatory mechanisms will potentially uncover pharmacological targets to prevent and treat thrombosis without adversely affecting haemostasis.